Merger and Acquisition Trends in Pharma – Q2 2026
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
Scope
This report provides an overview of M&A activity globally in Q2 2026 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q2 2026 in the Pharma sector.
Key Highlights
In Q2 2026, global pharma deal value rose to $101.5 billion, an 84.2% increase from Q1 2026. Deal volume also inched up 4.2%, with 124 M&A transactions. Oncology emerged as the leading therapeutic area recording 44 deals.
Reasons to Buy
Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Organon
Merck
Bio-Techne Corp
AbbVie
Apogee Therapeutics
GSK
Nuvalent
Eli Lilly
Kelonia Therapeutics
Gilead Sciences
Tubulis
Angelini Pharma
Catalyst Pharmaceuticals
Neurocrine Biosciences
Soleno Therapeutics
Bayer
Perfuse Therapeutics
Eli Lilly
Ajax Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports